|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Marco M, Di Cicilia R, Macchini M,
Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic
pancreatic cancer: Is gemcitabine still the best standard
treatment? (Review) Oncol Rep. 23:1183–1192. 2010.
|
|
5
|
Meyerson M, Gabriel S and Getz G: Advances
in understanding cancer genomes through second-generation
sequencing. Nat Rev Genet. 11:685–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feig C, Gopinathan A, Neesse A, Chan DS,
Cook N and Tuveson DA: The pancreas cancer microenvironment. Clin
Cancer Res. 18:4266–4276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collins MA and Pasca di Magliano M: Kras
as a key oncogene and therapeutic target in pancreatic cancer.
Front Physiol. 4:4072014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan XG, Yang ZL, Yang LP and Miao XY:
Expression of DNA-repair proteins and their significance in
pancreatic cancer and non-cancerous pancreatic tissues of
Sprague-Dawley rats. World J Surg Oncol. 12:322014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hruban RH, Goggins M, Parsons J and Kern
SE: Progression model for pancreatic cancer. Clin Cancer Res.
6:2969–2972. 2000.PubMed/NCBI
|
|
10
|
Iacobuzio-Donahue CA, Velculescu VE,
Wolfgang CL and Hruban RH: Genetic basis of pancreas cancer
development and progression: insights from whole-exome and
whole-genome sequencing. Clin Cancer Res. 18:4257–4265. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yachida S, White CM, Naito Y, Zhong Y,
Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA,
Herman JM, et al: Clinical significance of the genetic landscape of
pancreatic cancer and implications for identification of potential
long-term survivors. Clin Cancer Res. 18:6339–6347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takashima A and Faller DV: Targeting the
RAS oncogene. Expert Opin Ther Targets. 17:507–531. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Diersch S, Wenzel P, Szameitat M, Eser P,
Paul MC, Seidler B, Eser S, Messer M, Reichert M, Pagel P, et al:
Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer
cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Oncotarget. 4:277–288. 2013.PubMed/NCBI
|
|
16
|
Williams TM, Flecha AR, Keller P, Ram A,
Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A
and Sebolt-Leopold J: Cotargeting MAPK and PI3K signaling with
concurrent radiotherapy as a strategy for the treatment of
pancreatic cancer. Mol Cancer Ther. 11:1193–1202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Javle M, Li Y, Tan D, Dong X, Chang P, Kar
S and Li D: Biomarkers of TGF-β signaling pathway and prognosis of
pancreatic cancer. PLoS One. 9:e859422014. View Article : Google Scholar
|
|
19
|
Chow JY, Dong H, Quach KT, Van Nguyen PN,
Chen K and Carethers JM: TGF-beta mediates PTEN suppression and
cell motility through calcium-dependent PKC-alpha activation in
pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol.
294:G899–G905. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adeno-carcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leung L, Radulovich N, Zhu CQ, Wang D, To
C, Ibrahimov E and Tsao MS: Loss of canonical Smad4 signaling
promotes KRAS driven malignant transformation of human pancreatic
duct epithelial cells and metastasis. PLoS One. 8:e843662013.
View Article : Google Scholar
|
|
22
|
Blackford A, Serrano OK, Wolfgang CL,
Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ,
Eshleman JR, et al: SMAD4 gene mutations are associated with poor
prognosis in pancreatic cancer. Clin Cancer Res. 15:4674–4679.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oshima M, Okano K, Muraki S, Haba R, Maeba
T, Suzuki Y and Yachida S: Immunohistochemically detected
expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4)
strongly predicts survival in patients with resectable pancreatic
cancer. Ann Surg. 258:336–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garcia-Carracedo D, Turk AT, Fine SA,
Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger
JM, Remotti HE and Su GH: Loss of PTEN expression is associated
with poor prognosis in patients with intraductal papillary mucinous
neoplasms of the pancreas. Clin Cancer Res. 19:6830–6841. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lovejoy CA, Li W, Reisenweber S, Thongthip
S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, et al:
ALT Starr Cancer Consortium: Loss of ATRX, genome instability, and
an altered DNA damage response are hallmarks of the alternative
lengthening of telomeres pathway. PLoS Genet. 8:e10027722012.
View Article : Google Scholar
|
|
26
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Australian Pancreatic Cancer Genome Initiative: Whole genomes
redefine the mutational landscape of pancreatic cancer. Nature.
518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong X, Li Y, Hess KR, Abbruzzese JL and
Li D: DNA mismatch repair gene polymorphisms affect survival in
pancreatic cancer. Oncologist. 16:61–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hargreaves DC and Crabtree GR:
ATP-dependent chromatin remodeling: Genetics, genomics and
mechanisms. Cell Res. 21:396–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012.
|
|
30
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al: Australian Pancreatic Cancer Genome Initiative: Pancreatic
cancer genomes reveal aberrations in axon guidance pathway genes.
Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jones S, Li M, Parsons DW, Zhang X,
Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D,
et al: Somatic mutations in the chromatin remodeling gene ARID1A
occur in several tumor types. Hum Mutat. 33:100–103. 2012.
View Article : Google Scholar
|
